Melillo B, Liang S, Park J, Schön A, Courter JR, LaLonde JM, Wendler DJ, Princiotto AM, Seaman MS, Freire E, Sodroski J, Madani N, Hendrickson WA, Smith AB 3rd. Small-Molecule CD4-Mimics: Structure-Based Optimization of HIV-1 Entry Inhibition. ACS Med Chem Lett. 2016, 7(3):330-4.
Bournazos S, Gazumyan A, Seaman MS, Nussenzweig MC, Ravetch JV. Bispecific anti-HIV Antibodies with Enhanced Breadth and Potency. Cell. 2016, 165(7):1609-20.
McGuire AT, Gray MD, Dosenovic P, Gitlin AD, Freund NT, Petersen J, Correnti C, Johnsen W, Kegel R, Stuart AB, Glenn J, Seaman MS, Schief WR, Strong RK, Nussenzweig MC, Stamatatos L. Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice. Nat. Commun. 2016, 7:10618.
Cosgrove CA, Lacey CJ, Cope AV, Bartolf A, Morris G, Yan C, Baden S, Cole T, Carter D, Brodnicki E, Shen X, Joseph S, DeRosa SC, Peng L, Yu X, Ferrari G, Seaman M, Montefiori DC, Frahm N, Tomaras GD, Stöhr W, McCormack S, Shattock RJ. Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study. PLoS One. 2016, 11(5):e0152038.
Asbach B, Kliche A, Köstler J, Perdiguero B, Esteban M, Jacobs BL, Montefiori DC, LaBranche CC, Yates NL, Tomaras GD, Ferrari G, Foulds KE, Roederer M, Landucci G, Forthal DN, Seaman MS, Hawkins N, Self SG, Sato A, Gottardo R, Phogat S, Tartaglia J, Barnett SW, Burke B, Cristillo AD, Weiss DE, Francis J, Galmin L, Ding S, Heeney JL, Pantaleo G, Wagner R. Streamlining Heterologous DNA-Prime and NYVAC/Protein-Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. J. Virol. 2016, 90(8):4133-49.
Song R, Pace C, Seaman MS, Fang Q, Sun M, Andrews CD, Wu A, Padte NN, Ho DD. Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies. J Acquir Immune Defic Syndr. 2016 Dec 1;73(4):365-373.
Dev J, Park D, Fu Q, Chen J, Ha HJ, Ghantous F, Herrmann T, Chan W, Liu Z, Frey G, Seaman MS, Chen B, Chou JJ. Structural Basis for Membrane Anchoring of HIV-1 Envelope Spike. Science. 2016, 353(6295): 172-5.
Rademeyer C, Korber B, Seaman MS, Giorgi EE, Thebus R, Robles A, Sheward DJ, Wagh K, Garrity J, Carey BR, Gao H, Greene KM, Tang H, Bandawe GP, Marais JC, Diphoko TE, Hraber P, Tumba N, Moore PL, Gray GE, Kublin J, McElrath MJ, Vermeulen M, Middelkoop K, Bekker LG, Hoelscher M, Maboko L, Makhema J, Robb ML, Karim SA, Karim QA, Kim JH, Hahn BH, Gao F, Swanstrom R, Morris L, Montefiori DC, Williamson C. Elucidating the target of HIV-1 active and passive immunization studies: features of recently transmitted HIV-1 clade C viruses that impact antibody recognition. PLos Pathogens. 2016, 12(7):e1005742.
Zolla-Pazner S, Cohen SS, Boyd D, Kong XP, Seaman M, Nussenzweig M, Klein F, Overbaugh J, Totrov M. Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity. J. Virol. 2015, 90(2):636-49.
Huang Y, Yu J, Lanzi A, Yao X, Andrews CD, Tsai L, Gajjar MR, Sun M, Seaman MS, Padte NN, Ho DD. Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity. Cell. 2016, 165(7): 1621-31.
3 Blackfan Circle
Boston, MA 02115 – USA
T 617.667.7000
F 617.735.4566
E CVVRcontact@bidmc.harvard.edu
T 617.735.4610
E CVVRtrials@bidmc.harvard.edu
[DISPLAY_ULTIMATE_SOCIAL_ICONS]